Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

  1. Peeters, M.
  2. Price, T.
  3. Hotko, Y.
  4. Cervantes, A.
  5. Ducreux, M.
  6. Andre, T.
  7. Chan, E.
  8. Lordick, F.
  9. Rong, A.
  10. Gansert, J.
Revue:
EJC SUPPLEMENTS

ISSN: 1359-6349,  1878-1217

Année de publication: 2009

Volumen: 7

Número: 3

Pages: 10-10

Congreso: 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology

Type: Communication dans un congrès

DOI: 10.1016/S1359-6349(09)72049-X GOOGLE SCHOLAR
La source de données: WoS